Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
NCT04855253 · Masonic Cancer Center, University of Minnesota · PHASE1/PHASE2 · suspended · last registry update 2026-11-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Accrual met” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EEF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-04Results posted on the registry: AbbVie, IMGN632 (NCT03386513)
- 2026-06-25Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dose Escalation -tagraxofusp-erzs + Dose Expansion at RP2D -tagraxofusp-erzs (NCT05716009)
- 2026-05-18Also stopped (withdrawn): Virogen Biotechnology Inc., A-dmDT390-bisFv(UCHT1) + Vorinostat (NCT02943642)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision